(WO201748823) Disclosed herein are immunogenic glycopeptide compounds for inducing immune responses to prevent and/or treat cancer. Other aspects of the present disclosure are pharmaceutical compositions comprising the immunogenic glycopeptide compounds, and methods using the compounds for preventing and/or treating a cancer in a subject.
(WO201748823) 1. An immunogenic glycopeptide compound, wherein the compound has structural formula (I): (I) wherein P is a carbohydrate antigen selected from Globo H, SSEA4, GD2, GD3, GM2, fucosyl GM1, lewis y Le(y), sialyl-Le(x), sialyl-Le(a), TF, Tn and sialyl-Tn; m = 1 to 4; Y is a pan-DR epitope comprising an amino acid sequence at least 80% identical to AKXVAAWTLKAAA (SEQ ID NO: 1), wherein X is an amino acid residue selected from cyclohexylalanine, phenylalanine, and tyrosine; and n = 1 to 5.
(WO201748823) LEGAL DETAILS FOR WO2017048823 Actual or expected expiration date=2019-03-18 Legal state=ALIVE Status=PENDING Event publication date=2016-09-14 Event code=WO/APP Event indicator=Pos Event type=Examination events Application details Application country=WO WOUS2016051702 Application date=2016-09-14 Standardized application number=2016WO-US51702 Event publication date=2017-03-23 Event code=WO/A1 Event type=Examination events Published application with search report Publication country=WO Publication number=WO2017048823 Publication stage Code=A1 Publication date=2017-03-23 Standardized publication number=WO201748823 LEGAL DETAILS FOR DESIGNATED STATE EP Actual or expected expiration date=2035-09-18 Legal state=ALIVE Status=PENDING Corresponding cc: Designated or member state=EP Corresponding appl: EP16847220 Event publication date=2017-05-10 Event code=WO/121 Event type=Designated states EP: The EPO has been informed by wipo that ep was designated in this application Corresponding cc: Designated or member state=EP